Question special
Lead Moderator

The authors newly define the ’low-risk’ group of patients as having a recurrence score of ≤10, compared to the higher ‘standard’ cutoff score of <18 for low-risk designation. Is there strong enough evidence to continue to define the low-risk group as ≤10, or should it remain higher (e.g. <18) until there is clear evidence that the group of patients with a recurrence score of 11-17 are mid-range risk, and not low-risk?